Document text
Principal Investigator: BARBARA K FELBER
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2022
Award: $704,873
Funding agency: National Cancer Institute
We have been studying the immune response of COVID-19 cohorts longitudinally to characterize the nature and longevity of immune response (Rosati M, Am J Hematol: 97:E3, 2022; Rosati Frontiers Immunol 12: 793953, 2021; Thomopoulos, Viruses 1:1844; 2021; Terpos, Eur J Intern Med, 89:87,2021; Pappa, Microorganisms 9, 806, 2021; Terpos, Microorganisms. 8:1885, 2020). The analysis of natural infection is providing important information for the design of vaccine strategies. To characterize adaptive and innate immune responses in SARS-CoV2 vaccinated persons, we identified early responses to vaccination that are important in shaping both humoral and cellular protective immunity (Bergamaschi, Cell Rep 36:109504; 2021; Bergamaschi, Frontiers Immunol 3:899972, 2022). We characterized the cytokine and chemokine responses to BNT162b2 mRNA (Pfizer/BioNtech) vaccinations in antigen-naive and in previously COVID-19-infected individuals and in patients with hematological malignancies (NCT04743388). We identified a systemic signature including IL-15, IFN-gamma, IP-10/CXCL10, TNF-alpha and IL-6. Transient increases in IL-15 and IFN-gamma levels early after boost correlated with Spike antibody levels, supporting their use as biomarkers of effective humoral immunity development in response to vaccination. We expanded our studies to immunocompromised individuals including patients with hematological malignancies, a population at high risk of developing severe disease upon SARS-CoV-2 infection. Protection afforded by vaccination is frequently low and the biology leading to altered vaccine efficacy is not fully understood. Overall, the patients showed heterogeneous adaptive and innate responses with lower humoral (binding and neutralizing antibodies) and reduced innate cytokine responses (IFN-gamma, IL-15 and IP-10/CXCL10 signature) to vaccination compared to naive vaccine recipients. Changes in IFN-gamma and IP-10/CXCL10 at priming vaccination and IFN-gamma, IL-15, IL-7 and IL-10 upon booster vaccination correlated with the Spike antibody magnitude and were predictive of successful antibody development. The pattern of responses described offer novel prognostic approaches for potentiating the effectiveness of COVID-19 vaccination in transplant patients with hematological malignancies. We are expanding our research of the development of adaptive and innate immune responses upon COVID-19 vaccination to other cancer cohorts.
Terms: <(TNF)-α><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Antibodies><Antigens><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BNT 162b2><BNT162b2><BSF-2><BSF2><Binding><Biological Markers><Biology><Booster Immunization><COVID-19><COVID-19 immune response><COVID-19 infection><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 immune response><COVID19 infection><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CRG-2><CSIF><CSIF-10><CV-19><CV19><CXCL10><CXCL10 gene><Cachectin><Cancer Patient><Cancers><Cell Body><Cells><Chemotactic Cytokines><CoV-2><CoV2><Cytokine Synthesis Inhibitory Factor><Development><Development and Research><Disease><Disorder><Effectiveness><Gamma interferon><Goals><HPGF><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Hepatocyte-Stimulating Factor><Homologous Chemotactic Cytokines><Humoral Immunities><Hybridoma Growth Factor><IFI10><IFN-Gamma><IFN-beta 2><IFN-g><IFN-γ><IFNB2><IFNG><IFNγ><IL-10><IL-15><IL-6><IL-7><IL-7 Gene><IL10><IL10A><IL15><IL15 Protein><IL6 Protein><IL7><IL7 Protein><IL7 gene><INP10><IP-10><Immune Interferon><Immune response><Immunity><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunological response><Immunosuppressed Host><Individual><Infection><Innate Immune Response><Intercrines><Interferon Gamma><Interferon Type II><Interferon-gamma><Interleukin 10 Precursor><Interleukin 7 Precursor><Interleukin 7 Precursor Gene><Interleukin-10><Interleukin-15><Interleukin-15 Precursor><Interleukin-6><Interleukin-7><Interleukin-7 Gene><Internships><Length of Life><Long-term cohort><Longevity><Longitudinal cohort><Longterm cohort><Lymphopoietin-1><MGC9721><MGI-2><MOB-1><Macrophage-Derived TNF><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Messenger RNA><Molecular Interaction><Monocyte-Derived TNF><Myeloid Differentiation-Inducing Protein><Nature><Patients><Pattern><Persons><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Plasmacytoma Growth Factor><Population><R & D><R&D><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 immune response><SARS-CoV-2 infection><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 infection><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SCYB10><SIS cytokines><Secondary Immunization><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 immune response><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Shapes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Transplant Recipients><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Vaccinated><Vaccination><Vaccine Design><Vaccinee><Vaccines><Virus><Wuhan coronavirus><antibody-based immunity><bio-markers><biologic marker><biomarker><booster vaccination><chemoattractant cytokine><chemokine><cohort><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 immune response><coronavirus disease 2019 infection><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><developmental><frontier><gIP-10><hCoV19><high risk><host response><immune system response><immunogen><immunoresponse><immunosuppressed patient><individual patient><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interferon beta 2><intern><lFN-Gamma><life span><lifespan><mRNA><malignancy><microorganism><nCoV2><neoplasm/cancer><neutralizing antibody><novel><prognostic><research and development><response><transplant patient><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine efficacy><vaccine for novel coronavirus><vaccine strategy>